A Randomized, Double Blind, Placebo-controlled, Single Dose, Dose-escalation Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics After Intravenous DWJ1521 Administration in Healthy Adult Volunteers
Latest Information Update: 06 Mar 2023
At a glance
- Drugs DWJ 1521 (Primary) ; Fexuprazan
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Daewoong Pharmaceutical
Most Recent Events
- 08 Jun 2021 Planned primary completion date changed from 30 Apr 2021 to 30 Jun 2021.
- 08 Apr 2021 New trial record